During the past decade, Tianjin Chest Hospital conducted 67 clinical trials. In the 10-year time frame, 67 clinical trials started and 3 clinical trials were completed, i.e. on average, 4.5% percent of trials that started reached the finish line to date. In the past 5 years, 31 clinical trials started and 3 clinical trials were completed. i.e. 9.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Tianjin Chest Hospital" #1 sponsor was "Tianjin Chest Hospital" with 6 trials, followed by "Harbin Medical University" with 5 trials sponsored, "Chia Tai Tianqing Pharmaceutical Group Co., Ltd." with 3 trials sponsored, "Tang-Du Hospital" with 3 trials sponsored and "BeiGene" with 3 trials sponsored. Other sponsors include 55 different institutions and companies that sponsored additional 57 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Tianjin Chest Hospital" #1 collaborator was "LinkDoc Technology (Beijing) Co. Ltd." with 8 trials as a collaborator, "Tianjin Chest Hospital" with 5 trials as a collaborator, "Beijing Anzhen Hospital" with 2 trials as a collaborator, "Second Affiliated Hospital of Nanchang University" with 2 trials as a collaborator and "The First Affiliated Hospital of Nanchang University" with 2 trials as a collaborator. Other collaborators include 46 different institutions and companies that were collaborators in the rest 54 trials.

According to Clinical.Site data, the most researched conditions in "Tianjin Chest Hospital" are "Coronary Artery Disease" (7 trials), "Non-small Cell Lung Cancer" (4 trials), "Acute Coronary Syndrome" (3 trials), "Heart Failure" (3 trials) and "Percutaneous Coronary Intervention" (3 trials). Many other conditions were trialed in "Tianjin Chest Hospital" in a lesser frequency.

Most popular intervention types in "Tianjin Chest Hospital" are "Drug" (36 trials), "Procedure" (14 trials), "Device" (13 trials), "Other" (6 trials) and "Diagnostic Test" (4 trials). Other intervention types were less common.

The name of intervention was led by "Surgeries" (7 trials), "Placebo" (6 trials), "Letrozole" (2 trials), "Zanubrutinib" (2 trials) and "Zavicefta, Ceftazidime-Avibactam" (2 trials). Other intervention names were less common.

The vast majority of trials in "Tianjin Chest Hospital" are 77 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are 32 active trials in "Tianjin Chest Hospital". 1 are not yet recruiting, 25 are recruiting, 3 are Active, not recruiting, and 3 are Enrolling by invitation. In total, there were 28 completed trials in Tianjin Chest Hospital, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Tianjin Chest Hospital, 3 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 11 trials, and there were also 24 trials that are defined as “Not Applicable".